O8 Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematosus in men, ethnicities, and early disease. (23rd March 2020)

• Record Type: Journal Article
• Authors: Aringer, Martin; Brinks, Ralph; Costenbader, Karen; Boumpas, Dimitrios; Daikh, David; Jayne, David; Kamen, Diane L; Mosca, Marta; Ramsey-Goldman, Rosalind; Smolen, Josef S; Wofsy, David; Diamond, Betty; Jacobsen, Søren; Joseph McCune, W; Ruiz-Irastorza, Guillermo; Schneider, Matthias; Urowitz, Murray; Bertsias, George; Hoyer, Bimba; Leuchten, Nicolai; Tani, Chiara; Tedeschi, Sara K; Touma, Zahi; Anic, Branimir; Assan, Florence; Chan, Tak Mao; Clarke, Ann E; Crow, Peggy; Czirjak, Lazlo; Doria, Andrea; Graninger, Winfried; Halda-Kiss, Bernadette; Hasni, Sarfaraz A; Izmirly, Peter M; Jung, Michelle; Kumanovics, Gabor; Mariette, Xavier; Padjen, Ivan; Pego-Reigosa, JM; Romero-Díaz, Juanita; Rúa-Figueroa, Iñigo; Seror, Raphaele; Stummvoll, Georg; Tanaka, Yoshiya; Tektonidou, Maria; Vasconcelos, Carlos; Vital, Edward M; Wallace, Daniel J; Yavuz, Sule; Naden, Raymond P; Dorner, Thomas; Johnson, Sindhu;
• Is Part Of: Lupus science & medicine. Volume 7(2020)Supplement 1
• Page Start: A11
• Page End: A12
• Publication Date: 2020-03-23
• Subjects: Systemic lupus erythematosus -- Periodicals; 616.772005
• DOI: 10.1136/lupus-2020-eurolupus.21
• Languages: English
• ISSNs: 2398-8851

Abstract

Abstract : Background: Supported by both the ACR and EULAR, the EULAR/ACR 2019 Classification Criteria for SLE employ positive ANA (ever) as an entry criterion and use a weighted scheme with values ranging from 2 to 10, for a classification cut-off of 10. Criteria items are attributed to SLE only if there is no more likely alternative diagnosis in the individual patients. Items are organized in domains, and only the highest ranking item within a domain is counted. These criteria have been validated in a cohort of 696 SLE patients and 574 non-SLE patients from a total of 21 centers, reaching an overall sensitivity of 96.1% and a specificity of 93.4%. To at least estimate the performance in groups underrepresented in the validation cohort of this transatlantic project, we analyzed this cohort for patient subsets with regard to sex, ethnicity, and disease duration. Methods: The full EULAR/ACR 2019 classification criteria validation cohort was analyzed for female (n=1, 098) and male (n=172) patients, Asian (n=118), Black (n=68), Hispanic (n=124) and White (n=941) patients, and patients with an SLE duration of less than 1 year (n=34), one to less than 3 years (n=196), 3 to less than 5 years (n=157), and 5 or more years (n=879). Sensitivity and specificity were calculated for the EULAR/ACR 2019 criteria, the SLICC 2012 criteria and the ACR 1997 criteria each. Results: As shown in table 1, most of the point estimates for sensitivity and specificity in subsets lay within the 95% confidence intervals of the sensitivity and specificity of the EULAR/ACR 2019 criteria validation. In particular, sensitivity and specificity for all ethnic groups were within the confidence intervals or even higher. Formally, the sensitivity was slightly lower for male patients, corresponding to a higher specificity, but the male 95% confidence intervals (0.86–0.98 for sensitivity, 0.90–0.99 for specificity) overlapped. While sensitivity appeared independent of disease duration from year 1 on, sensitivity was only 89% in the first year of disease, identical to the SLICC criteria (89%) and numerically higher than the ACR criteria (56%), but all confidence intervals overlapped. Conclusion: While not all subgroups of SLE patients in the validation cohort are of adequate size to fully explore the sensitivity and specificity of the EULAR/ACR 2019 SLE classification criteria in the respective subsets, the point estimates of sensitivity and specificity suggest that the new criteria perform at least reasonably well in all ethnic groups, in men and in early disease. Nevertheless, sensitivity and specificity should be independently validated in larger groups of Asian, Black and Hispanic patients, male patients and in early disease.